This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Trial of octreotide in recurrent variceal bleeding

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

32 patients with biopsy-proven hepatic cirrhosis and a first variceal bleed were randomised to sclerotherapy alone or sclerotherapy plus six months of octreotide therapy.

The patients and clinicians were not blinded.

The main outcomes reported were:

  • frequency of rebleeding:
    • during the 6 months of the trial the number of patients who rebled was:
      • 1/16 in the combined octreotide/sclerotherapy group
      • 7/16 in the sclerotherapy alone group
      • p=0.037

  • mortality:
    • during the 6 months the mortality rate was:
      • 0/16 in the combined octreotide/sclerotherapy group
      • 5/16 in the sclerotherapy alone group
      • p<0.02



  • change in portal pressure:
    • during the 6 months the change in portal pressure was:
      • -6.0 mmHg in the combine treatment group
      • +1.5 mmHg in the sclerotherapy alone group

Reference:

  • Jenkins, SA. et al. (1997). Randomised trial of octreotide for long term management of cirrhosis after variceal haemorrhage. BMJ, 315, 1138-41.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.